NICE recommend dapagliflozin for treating chronic kidney disease
The National Institute for Health and Care Excellence (NICE) has recommended dapagliflozin as an option for treating certain individuals with chronic kidney disease (CKD) in new draft guidance.
November 9, 2021
by EuropeanPharmaceuticalReview
NICE recommends AstraZeneca’s dapagliflozin to treat chronic kidney disease
The UK’s National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s dapagliflozin as a treatment for people with chronic kidney disease (CKD).
November 9, 2021
by Pharmaceutical-Business-Review
No Increase in Risk With Dapagliflozin in Patients With Stage 4 CKD
For patients with stage 4 chronic kidney disease (CKD), a similar pattern of reduced kidney, cardiovascular, and mortality risks is seen with dapagliflozin versus placebo, with no evidence of increased risks.
July 22, 2021
by drugs
Da-pag-li-flo-zin is Well Tolerated in Hospitalized Patients
DARE-19 is the first large randomized clinical trial to assess sodium-glucose cotransporter-2 (SGLT2) inhibitors in patients with and without type 2 diabetes hospitalized with COVID-19.
June 28, 2021
by firstwordpharma
Mankind Pharma launches Justoza, a Dapagliflozin approved by USFDA
The Active Pharmaceutical Ingredient (API) is procured from the Drug Master File (DMF) facility approved by USFDA, EU GMP and WHO GMP, which ensures the highest global efficacy and safety standards.
June 23, 2021
by expresspharma
Astrazeneca gives rights to trademark for three diabetes drug brands to Sun Pharma
Consequently, AstraZeneca India and Sun Pharma have discontinued their existing distribution services agreement signed in 2016, for the distribution of Dapagliflozin.
May 31, 2021
by expresspharma
Micro Labs launches anti-diabetic drug combo, Dapagliflozin plus Metformin
The drug comes in two strengths ZUCAPRIDE–M 500 priced at Rs12.80 per tablet and ZUCAPRIDE–M 1000 at Rs 14.80.
November 25, 2020
by expresspharma
Zydus Cadila gets tentative US FDA approval for Dapagliflozin Tablets
Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated to improve glycemic control in adults with type 2 diabetes mellitus.
October 30, 2020
by expresspharma
Diabetes drug, Dapagliflozin shows benefits in patients with CKD
The drug, on top of standard of care, reduced the composite measure of worsening of renal function or risk of cardiovascular (CV) or renal death by 39 per cent.
September 1, 2020
by expresspharma
Astrazeneca’s Dapagliflozin gets DCGI nod for treatment of heart failure
Dapagliflozin (Forxiga) is an SGLT-2 inhibitor that can reduce the risk of cardiovascular death and hospitalisation for heart failure in patients with HFrEF.
July 6, 2020
by expresspharma
Glenmark gets tentative USFDA approval for generic anti-diabetes tablets
The approval is for the strength of 10 mg/5 mg tablets of Dapagliflozin and Saxagliptin.
April 29, 2020
by expresspharma
Dapagliflozin Lowers Risk for Worsening Heart Failure
For patients with heart failure and reduced ejection fraction, dapagliflozin is associated with a lower risk for worsening heart failure or death from cardiovascular causes, regardless of the presence of type 2 diabetes ...
September 24, 2019
by drugs